Mumbai:Cipla Limitedhas announced that it has entered into definitive agreements to acquire 100 percent stake in Inzpera Healthsciences Limited, a company specializing in paediatric pharmaceutical and wellness products. Following the transaction, Inzpera will become wholly owned subsidiary of the Company. As per the BSE filing, theacquisitionmarks a strategic move to combine Inzpera’s extensive portfolio of paediatric pharmaceutical and wellness products with Cipla's strong distribution network and operational capabilities to drive growth and scalability. The enterprise value of Inzpera is Rs 120 crores. After accounting for necessary working capital adjustments, the purchase consideration has been determined to be Rs 110.65 crores for acquisition of equity shares and non-convertible redeemable preference shares, representing 100% of Inzpera’s shareholding. The final consideration remains subject to adjustments on the closing date. The acquisition is expected to be completed within one month from the signing of the transaction documents or by such other timelines as maybe mutually agreed between the parties. Meanwhile,Cipla Ltdreported a 3.7 percent surge in Q2 consolidated net profit at Rs 1,353.37 crore. The pharma major had reported a consolidated net profit of Rs 1,305.01 crore in the same period last year. Consolidated total revenue from operations rose to Rs 7,589.44 crore in the second quarter from Rs 7,051.02 crore in the year-ago period. Read also:Cipla profit up 3.7 percent at Rs 1353 crore in Q2 Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in its home markets of India, South Africa, North America, and key regulated and emerging markets. The company strengths lies in the respiratory, anti-retroviral, urology, cardiology, antiinfective and CNS segments. Cipla 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 74+ markets.